Oric Pharmaceuticals, Inc. (ORIC)
Health Care ยท Pharmaceutical Preparations
Oric Pharmaceuticals, Inc. (ORIC) is listed on Nasdaq, where its shares have traded since April 24, 2020. SentiSense covers Oric Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Jacob M. Chacko is its chief executive officer. The company reports 111 employees, and its corporate website is www.oricpharma.com.
About Oric Pharmaceuticals, Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Latest reported results
ORIC Pharmaceuticals, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 172 institutions reported holding ORIC, with 123.4 million shares worth $1.3 billion in aggregate. The largest reported holders were Nextech Invest, Ltd, BlackRock and Ecor1 Capital. Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter.
More on ORIC
- ORIC sentiment: whether news and social coverage of Oric Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- ORIC ownership: all 172 reporting institutions, plus insider and congressional trades.
- ORIC financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Oric Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Oric Pharmaceuticals, Inc. do?
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
What sector is ORIC in?
SentiSense classifies Oric Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ORIC stock trade?
Oric Pharmaceuticals, Inc. (ORIC) is listed on Nasdaq, where its shares have traded since April 24, 2020.
Who is the CEO of Oric Pharmaceuticals, Inc.?
Jacob M. Chacko is the chief executive officer of Oric Pharmaceuticals, Inc..